David Shaw’s Centessa Pharmaceuticals CNTA Stock Holding History

David Shaw’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-643,808	Closed	-$25.6M	–	4913
2026 Q1	$25.6M	Sell	643,808 -187,828	-23%	-$4.8M	0.02%	1001
2025 Q4	$20.8M	Buy	831,636 +767,247	+1,192%	+$19.4M	0.01%	1223
2025 Q3	$1.56M	Buy	64,389 +48,625	+308%	+$864K	﹤0.01%	3157
2025 Q2	$207K	Buy	+15,764	New	+$200K	﹤0.01%	4042
2024 Q4	–	Sell	-48,078	Closed	-$769K	–	4458
2024 Q3	$769K	Buy	+48,078	New	+$589K	﹤0.01%	3447
2021 Q4	–	Sell	-12,420	Closed	-$207K	–	5447
2021 Q3	$207K	Buy	+12,420	New	+$257K	﹤0.01%	4553

David Shaw's CNTA Position: Q2 2026 in Review

David Shaw sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 643,808 shares — an estimated $25.6M sold.

David Shaw first reported a position in CNTA in Q3 2021 and held it in 6 quarters. The position peaked at $25.6M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

David Shaw reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
David Shaw sold 643,808 Centessa Pharmaceuticals shares in Q2 2026, an estimated $25.6M.
David Shaw first reported a position in Centessa Pharmaceuticals in Q3 2021 and held it in 6 quarters.
David Shaw's Centessa Pharmaceuticals position peaked at $25.6M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.